Novo Nordisk has unveiled a new pricing action aimed at making two of its popular products, Ozempic and Wegovy, more accessible to patients in the United States.
From 17 November 2025, new toner-pay cases can pierce the first two boluses for just $199 each, down from the former $499 yearly cost, in a move designed to ease the fiscal burden for those managing rotundity or type 2 diabetes.
Affordable Weight Loss and Diabetes Treatments
The limited-time offer applies to the two lowest doses of each medication (0.25 mg and 0.5 mg) and will run until 31 March 2026. After this initial period, the monthly cost for self-pay patients will increase to $349.
Novo Nordisk lowered prices for their #GLP1 medications for patients paying out-of-pocket—but the deal is only good for the first two months of treatment.
Existing cash-paying patients can get #Ozempic or #Wegovy for $349 per month. New patients can get the two lowest doses for… pic.twitter.com/wmnErsGWCU
— Health (@health_com_) November 18, 2025
Patients can take advantage of this offer through multiple channels:
- Over 70,000 pharmacies across the U.S.
- Home delivery via NovoCare Pharmacy
- Select telehealth providers, including GoodRx and Costco
A Step Towards Greater Accessibility
The new pricing comes after recent agreements with the U.S. Administration focused on increasing access to critical medications for chronic conditions.
Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk, highlighted the company’s commitment to making FDA-approved treatments affordable.
He stated: “We are dedicated to ensuring that more people can access the care they need safely and affordably.”
Why Ozempic and Wegovy Matter?
Both specifics contain semaglutide, a proven remedy for managing habitual conditions. Wegovy is specifically specified for grown-ups living with obesity, while Ozempic is extensively used to manage type 2 diabetes.
With nearly 40% of U.S. adults affected by rotundity and over 28 million living with type 2 diabetes, access to effective solutions has noway been more pivotal.
Support and Ongoing Savings Programs
Cases with marketable insurance can continue to profit from Novo Nordisk’s savings programs for Wegovy and Ozempic. Full details on pricing, content, and eligibility can be set up at NovoCare.com.
A Safer Alternative to Unsafe Weight Loss Methods
This tone-pay pricing action is part of Novo Nordisk’s broader trouble to expand access to semaglutide treatments, including weight loss injections and diabetes specifics.
By reducing cost walls, the company aims to help cases avoid unsafe decisions while entering clinically proven curatives.
With this new action, Novo Nordisk is making strides in public health by supporting grown-ups struggling with obesity and type 2 diabetes.
Further affordable access to Ozempic and Wegovy could offer relief to millions seeking safe, effective, and clinically approved treatments for weight management and blood sugar control.
